Thank you for including me in this session. I’m Bing Li, from Blood Disease Hospital, Chinese Academy of Medical Sciences. Today I will present the data from a clinical trial of flonoltinib, a novel JAK inhibitor from Zenitar, China. These are my disclosures.
Flonoltinib is a novel triple-target agent. First, it’s a highly selective JAK2 inhibitor. It inhibits both the JH1 domain and the JH2 pseudokinase domain, as well as FLT3 and CDK6...
Thank you for including me in this session. I’m Bing Li, from Blood Disease Hospital, Chinese Academy of Medical Sciences. Today I will present the data from a clinical trial of flonoltinib, a novel JAK inhibitor from Zenitar, China. These are my disclosures.
Flonoltinib is a novel triple-target agent. First, it’s a highly selective JAK2 inhibitor. It inhibits both the JH1 domain and the JH2 pseudokinase domain, as well as FLT3 and CDK6. This profile is intended to suppress several pathways involved in myelofibrosis, including the JAK-STAT pathway, NF-κB and TGF-β, among others. So flonoltinib may provide broader clinical activity and may modify the disease biology.
It was evaluated first in Phase I/IIa studies. Phase I was the dose-escalation stage, and 15 MF patients were included, all with measurable splenomegaly and platelet counts as low as 50. Based on the escalation, 100 mg daily was selected for the Phase IIa dose expansion, and in total 15 patients were included in the Phase IIa study.
Generally, the early studies indicate a very positive signal for flonoltinib in treating patients with myelofibrosis. At week 24, SVR35 was 77%, the best spleen response was 86%, and the best symptom response was 76%. Importantly, among patients with available driver mutation burden data, 17 of 18 patients had a reduction, with a reduction of over 20% in five patients. In terms of safety, the most common treatment-related adverse events were anemia and thrombocytopenia.
So we initiated a Phase IIb randomized study, head-to-head against ruxolitinib, to treat JAK inhibitor-naïve MF patients with higher-risk disease and large spleens. Patients were assigned in a 1:1:1 ratio to a lower-dose flonoltinib arm, 50 mg, a higher-dose flonoltinib arm, 100 mg, or label-based ruxolitinib. The study was designed to compare the spleen and symptom response and to characterize the safety of flonoltinib.
And before we look at the efficacy, please note the baseline imbalances highlighted on the right. Compared with the ruxolitinib arm, the flonoltinib arms had more patients with primary myelofibrosis, 82% versus 62%, more patients with transfusion dependency, 9.8% versus 4.2%, and more patients with lower platelets. In fact, no patients with lower platelet counts were included in the ruxolitinib arm. In addition, in the flonoltinib arms, more patients were classified as high risk according to the DIPSS or IPSS scoring systems, and more patients had CALR mutations, 33% versus 12%. We know CALR mutations may indicate less responsiveness to conventional JAK inhibitors, and more patients had severe fibrosis. Therefore, flonoltinib was evaluated in a more challenging population, so all this should be considered when interpreting the efficacy comparison.
And the primary endpoint is SVR35 at week 24. In the lower-dose flonoltinib arm, the SVR35 rate was 80%, and in the higher-dose arm it was 96%, compared with 66% for ruxolitinib. Particularly in CALR-mutated subgroups, 13 of 17 patients under flonoltinib treatment achieved SVR35, compared with only one of three patients in the ruxolitinib arm. The same pattern was also observed in the symptom response, TSS50 at week 24: lower dose 84% and higher dose 96%, compared with 58% for ruxolitinib. Similarly, in the CALR-mutated subgroup, 15 of 17 patients achieved TSS50, compared with only one of three patients on ruxolitinib. And for the dual endpoint, spleen and symptom response at week 24, in the lower-dose arm it was 68%, the higher dose 96%, and in the ruxolitinib arm 45%.
In subgroup analysis, it indicates that the flonoltinib response is not dependent on the different driver mutations, whether JAK2 V617F or CALR mutations. Flonoltinib spleen and symptom responses were much better than with ruxolitinib. We can also see that in patients with severe cytopenia, most of whom have lower platelet counts, between 50 and 100, there was almost the same activity as in patients with normal platelet counts.
And we can also see the treatment duration at the end of April this year. Forty-two of 51 patients under flonoltinib treatment, 82%, remained on treatment. The median treatment duration was almost one year, and the one-year discontinuation rate was 5.4%, supporting flonoltinib’s favorable long-term safety and tolerability. And at week 24, 20 patients under ruxolitinib treatment crossed over to flonoltinib. Among six ruxolitinib-resistant patients, five achieved SVR35 after crossover. This crossover experience indicates that flonoltinib retains strong clinical activity in patients after ruxolitinib failure.
In terms of safety, the hematological toxicity may still be a concern. Grade 3 or higher anemia occurred in 44% in the lower-dose flonoltinib arm and 76% in the higher-dose arm, and 58% with ruxolitinib. Thrombocytopenia and neutropenia were not very common, but still slightly more frequent than with ruxolitinib. Generally, the lower dose of flonoltinib showed favorable tolerability, and the higher dose of flonoltinib showed the strongest efficacy.
And based on these findings, a new Phase III study, head-to-head against ruxolitinib, is ongoing in China, and another Phase II study will open in North America. In addition, two Phase IIb studies are ongoing: one targeting JAK inhibitor-failure MF patients, and the other in patients with polycythemia vera.
In conclusion, flonoltinib produced high rates of spleen and symptom response in this randomized Phase IIb study, especially in patients with CALR mutations and patients with cytopenias. The 100 mg dose showed strong efficacy, while the 50 mg dose offered a favorable balance of activity and hematological tolerability. I would like to thank all the patients and their families in these studies, and also thank all the investigators and the medical teams from all sides. Thank you for your attention.
AI-generated transcript. Please refer to the video as the authoritative source.